These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 4028627)
21. Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial. Sparkes C; Gibson R; Sinclair A; Else PL; Meyer BJ Nutrients; 2018 Oct; 10(10):. PubMed ID: 30297663 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118 [TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243 [TBL] [Abstract][Full Text] [Related]
24. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR Artery; 1985; 12(6):363-81. PubMed ID: 4051756 [TBL] [Abstract][Full Text] [Related]
25. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054 [TBL] [Abstract][Full Text] [Related]
26. Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia. Shinomiya M; Ishikawa Y; Shirai K; Saito Y; Yoshida S Arzneimittelforschung; 1987 Sep; 37(9):1069-71. PubMed ID: 3435604 [TBL] [Abstract][Full Text] [Related]
27. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
28. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787 [TBL] [Abstract][Full Text] [Related]
29. Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids. Amar MJ; Kaler M; Courville AB; Shamburek R; Sampson M; Remaley AT Lipids Health Dis; 2016 Jul; 15(1):115. PubMed ID: 27405337 [TBL] [Abstract][Full Text] [Related]
31. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597 [TBL] [Abstract][Full Text] [Related]
32. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099 [TBL] [Abstract][Full Text] [Related]
33. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]. Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481 [TBL] [Abstract][Full Text] [Related]
34. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium. Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642 [TBL] [Abstract][Full Text] [Related]
36. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
37. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias. Campos CT; Matts JP; Fitch LL; Speech JC; Long JM; Buchwald H Surgery; 1990 Oct; 108(4):601-10; discussion 610-1. PubMed ID: 2120785 [TBL] [Abstract][Full Text] [Related]
38. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. Betteridge DJ; Bhatnager D; Bing RF; Durrington PN; Evans GR; Flax H; Jay RH; Lewis-Barned N; Mann J; Matthews DR BMJ; 1992 May; 304(6838):1335-8. PubMed ID: 1611329 [TBL] [Abstract][Full Text] [Related]
39. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705 [TBL] [Abstract][Full Text] [Related]
40. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. Leaf DA; Connor WE; Illingworth DR; Bacon SP; Sexton G JAMA; 1989 Dec; 262(22):3154-60. PubMed ID: 2681858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]